Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
MMWR Morb Mortal Wkly Rep. 2006 Mar 3;55(8):209-10.

A new product (VariZIG) for postexposure prophylaxis of varicella available under an investigational new drug application expanded access protocol.

Abstract

On October 27, 2004, the Advisory Committee on Immunization Practices (ACIP) was informed by the only U.S.-licensed manufacturer of varicella zoster immune globulin (VZIG) (Massachusetts Public Health Biologic Laboratories, Boston, Massachusetts) that the company had discontinued production of VZIG. The supply of the licensed VZIG product is now nearly depleted. In February 2006, an investigational (not licensed) VZIG product, VariZIG (Cangene Corporation, Winnipeg, Canada) became available under an investigational new drug application (IND) submitted to the Food and Drug Administration (FDA). This product can be requested from the sole authorized U.S. distributor, FFF Enterprises (Temecula, California), for patients who have been exposed to varicella and who are at increased risk for severe disease and complications.

PMID:
16511443
[PubMed - indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for CDC - Morbidity and Mortality Weekly Report
    Loading ...
    Write to the Help Desk